Presatovir in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

February 20, 2017

Study Completion Date

September 27, 2017

Conditions
Respiratory Syncytial Virus (RSV)
Interventions
DRUG

Presatovir

Tablets administered orally or via nasogastric (NG) tube once daily

DRUG

Placebo

Tablets administered orally or via NG tube once daily

Trial Locations (28)

Unknown

Phoenix

Los Angeles

San Francisco

Stanford

Tampa

Atlanta

Chicago

Maywood

New Orleans

Boston

Ann Arbor

Cleveland

Philadelphia

Pittsburgh

Dallas

San Antonio

Seattle

Sydney

Brisbane

Murdoch

Brussels

Yvoir

Toronto

Strasbourg

Hanover

Munich

Rotterdam

Cambridge

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY